Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 10, Issue 7, Pages e004879
Publisher
BMJ
Online
2022-07-07
DOI
10.1136/jitc-2022-004879
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma
- (2021) Alexander Chehrazi-Raffle et al. Cancers
- Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
- (2021) Razvan Cristescu et al. CLINICAL CANCER RESEARCH
- Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
- (2020) Harriet M. Kluger et al. Journal for ImmunoTherapy of Cancer
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
- (2020) Catherine S. Grasso et al. CANCER CELL
- WNT/β-catenin pathway activation correlates with immune exclusion across human cancers
- (2019) Jason J. Luke et al. CLINICAL CANCER RESEARCH
- Targeted genomic profiling of acral melanoma
- (2019) Iwei Yeh et al. JNCI-Journal of the National Cancer Institute
- Targeted Therapy and Immunotherapy for Melanoma in Japan
- (2019) Kenjiro Namikawa et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer
- (2019) Wenting Liao et al. CANCER CELL
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
- (2019) Tuba N. Gide et al. CANCER CELL
- A Review of the Role of Wnt in Cancer Immunomodulation
- (2019) Whitney N. Goldsberry et al. Cancers
- Wnt signaling and drug resistance in cancer
- (2019) Zheng Zhong et al. MOLECULAR PHARMACOLOGY
- WNT Signaling in Tumors: The Way to Evade Drugs and Immunity
- (2019) Elena Martin-Orozco et al. Frontiers in Immunology
- β-Catenin–mediated immune evasion pathway frequently operates in primary cutaneous melanomas
- (2018) Jérémie Nsengimana et al. JOURNAL OF CLINICAL INVESTIGATION
- Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- (2018) Catherine S. Grasso et al. Cancer Discovery
- Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
- (2018) Omid Hamid et al. BRITISH JOURNAL OF CANCER
- Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study
- (2018) Yoshiyuki Nakamura et al. JOURNAL OF DERMATOLOGY
- Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients
- (2018) T. Maeda et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
- (2018) Kenjiro Namikawa et al. EUROPEAN JOURNAL OF CANCER
- CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review
- (2018) Bagher Farhood et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
- (2017) Matthew A. Coelho et al. IMMUNITY
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
- (2017) Sandra P. D’Angelo et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole-genome landscapes of major melanoma subtypes
- (2017) Nicholas K. Hayward et al. NATURE
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- Analysis of Trends in US Melanoma Incidence and Mortality
- (2017) Alex M. Glazer et al. JAMA Dermatology
- Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma
- (2017) Daniel Y. Wang et al. Cancer Immunology Research
- The efficacy of anti-PD-1 agents in acral and mucosal melanoma
- (2016) Alexander N. Shoushtari et al. CANCER
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis
- (2016) Deborah Kuk et al. ONCOLOGIST
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Prognosis of Acral Melanoma: A Series of 281 Patients
- (2013) Danielle M. Bello et al. ANNALS OF SURGICAL ONCOLOGY
- Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study
- (2013) Nancy E. Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- (2013) Kristian Cibulskis et al. NATURE BIOTECHNOLOGY
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- OSA: a fast and accurate alignment tool for RNA-Seq
- (2012) Jun Hu et al. BIOINFORMATICS
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array Profiling
- (2011) Domenico Coppola et al. AMERICAN JOURNAL OF PATHOLOGY
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- (2011) Rui-Ru Ji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Gene Signature in Melanoma Associated With Clinical Activity
- (2010) Thomas F. Gajewski et al. CANCER JOURNAL
- CD11c+CD8+ T cells: Two-faced adaptive immune regulators
- (2010) Dass S. Vinay et al. CELLULAR IMMUNOLOGY
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
- (2010) A. McKenna et al. GENOME RESEARCH
- CD8+Foxp3+ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response
- (2010) Dung T. Le et al. INTERNATIONAL JOURNAL OF CANCER
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Environmental exposures and mutational patterns of cancer genomes
- (2010) Gerd P Pfeifer Genome Medicine
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
- (2009) H. Harlin et al. CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- A Modular Analysis Framework for Blood Genomics Studies: Application to Systemic Lupus Erythematosus
- (2008) Damien Chaussabel et al. IMMUNITY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started